Press releases
- Citius Pharmaceuticals to Host Investor Call to Discuss Topline Results of Phase 3 Trial of Mino-Lok Antibiotic Lock Solution
- Citius Pharmaceuticals Achieves Primary and Secondary Endpoints in Phase 3 Trial of Mino-Lok Antibiotic Lock Solution
- Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2024 Financial Results and Provides Business Update
- Citius Pharmaceuticals to Participate in Upcoming EF Hutton and H.C. Wainwright Investor Conferences
- Citius Pharmaceuticals Announces Closing of $15 Million Registered Direct Offering
- Citius Pharmaceuticals Announces $15 Million Registered Direct Offering
- Citius Pharmaceuticals Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma
- Citius Pharmaceuticals to Present at the LD Micro Invitational XIV Investor Conference
- Citius Pharmaceuticals Announces FDA Acceptance of the BLA Resubmission of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma
- Citius Pharmaceuticals, Inc. Secures $2.4 million through New Jersey Economic Development Program
More ▼
Key statistics
On Friday, Citius Pharmaceuticals Inc (47N:STU) closed at 0.6115, 11.69% above the 52 week low of 0.5475 set on Feb 06, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.5895 |
---|---|
High | 0.6115 |
Low | 0.5895 |
Bid | 0.5925 |
Offer | 0.6715 |
Previous close | 0.564 |
Average volume | 0.00 |
---|---|
Shares outstanding | 180.67m |
Free float | 168.37m |
P/E (TTM) | -- |
Market cap | 126.02m USD |
EPS (TTM) | -0.2367 USD |
Data delayed at least 15 minutes, as of May 31 2024.
More ▼